RxDoctor Payments Data

Lauren Litwak, OD

Optometrist · Norfolk, VANPI 1679200232

Payments from drug & device makers

$4,417in general payments, 2019–2025

Across 121 payments — averaging $36.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$981
  • Sun Pharmaceutical Industries Inc.$646
  • Alcon$492
  • Mallinckrodt Hospital Products Inc.$483
  • Tarsus Pharmaceuticals, Inc.$404
  • AbbVie$356
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$4,417100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,417 in reported general payments places this provider in the 90th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$165,344
Medicare patients
791
Services billed
1,999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine62$84,426
XiidraLifitegrast36$56,038
MieboPerfluorohexyloctane/Pf51$39,744
CequaCyclosporine31$29,472
LumiganBimatoprost22$14,315
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol41$10,606
Cyclosporine16$10,567
Prednisolone Acetate190$10,222
Alphagan PBrimonidine Tartrate20$10,012
CombiganBrimonidine Tartrate/Timolol21$8,599
VyzultaLatanoprostene Bunod16$7,323
Loteprednol Etabonate25$6,051
RhopressaNetarsudil Mesylate16$5,819
SimbrinzaBrinzolamide/Brimonidine Tart17$3,725
Brimonidine Tartrate153$3,661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$356$117,352125 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$981$103,106103 claims
Sun Pharmaceutical Industries Inc.Cequa$646$29,47231 claims
AlconSimbrinza$492$3,72517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →